187 related articles for article (PubMed ID: 26408008)
1. A phase II clinical trial to investigate the effect of pioglitazone on (18)F-FDG uptake in malignant lesions.
Han YH; Kwon SY; Kim J; Na CJ; Choi S; Min JJ; Bom HS; Kim YC; Oh IJ; Chae HJ; Lim ST; Sohn MH; Jeong HJ
EJNMMI Res; 2015 Dec; 5(1):50. PubMed ID: 26408008
[TBL] [Abstract][Full Text] [Related]
2. The effect of PPAR-γ agonist on (18)F-FDG PET imaging for differentiating tumors and inflammation lesions.
Cheong SJ; Lee CM; Kim EM; Lim ST; Sohn MH; Jeong HJ
Nucl Med Biol; 2015 Feb; 42(2):85-91. PubMed ID: 25441255
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Value of (18)F-FDG PET/CT in the Detection of Ovarian Malignancy.
Park T; Lee S; Park S; Lee E; Pahk K; Rhee S; Cho J; Kim C; Eo JS; Choe JG; Kim S
Nucl Med Mol Imaging; 2015 Mar; 49(1):42-51. PubMed ID: 25774237
[TBL] [Abstract][Full Text] [Related]
5. The effect of PPAR-gamma agonist on (18)F-FDG uptake in tumor and macrophages and tumor cells.
Kim SL; Kim EM; Cheong SJ; Lee CM; Kim DW; Jeong HJ; Lim ST; Sohn MH; Yim CY
Nucl Med Biol; 2009 May; 36(4):427-33. PubMed ID: 19423011
[TBL] [Abstract][Full Text] [Related]
6. Dual-time point
Parghane RV; Basu S
Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
[TBL] [Abstract][Full Text] [Related]
7. Pilot prospective evaluation of (18)F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer.
Minamimoto R; Karam A; Jamali M; Barkhodari A; Gambhir SS; Dorigo O; Iagaru A
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1047-55. PubMed ID: 26611425
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
[TBL] [Abstract][Full Text] [Related]
9. (18)F-FDG and (18)F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes.
Rayamajhi SJ; Mittal BR; Maturu VN; Agarwal R; Bal A; Dey P; Shukla J; Gupta D
Ann Nucl Med; 2016 Apr; 30(3):207-16. PubMed ID: 26661845
[TBL] [Abstract][Full Text] [Related]
10. Multiple values of
Li Y; Zhou Y; Wang Q
Clin Rheumatol; 2017 Oct; 36(10):2297-2305. PubMed ID: 28831580
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
[TBL] [Abstract][Full Text] [Related]
12. Different hydration protocols for the quantification of healthy tissue uptake of half-dose
Cao Y; Cai D; Sui X; Wang X; Song J; Tan H; Hu P; Zhang Y; Yu H; Shi H
Quant Imaging Med Surg; 2023 Sep; 13(9):5701-5712. PubMed ID: 37711806
[TBL] [Abstract][Full Text] [Related]
13. Comparisons between glucose analogue 2-deoxy-2-((18)F)fluoro-D-glucose and (18)F-sodium fluoride positron emission tomography/computed tomography in breast cancer patients with bone lesions.
Capitanio S; Bongioanni F; Piccardo A; Campus C; Gonella R; Tixi L; Naseri M; Pennone M; Altrinetti V; Buschiazzo A; Bossert I; Fiz F; Bruno A; DeCensi A; Sambuceti G; Morbelli S
World J Radiol; 2016 Feb; 8(2):200-9. PubMed ID: 26981229
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of small pulmonary nodules with little or no 18F-FDG uptake on PET/CT images of patients with nonthoracic malignancies.
O JH; Yoo IeR; Kim SH; Sohn HS; Chung SK
J Nucl Med; 2007 Jan; 48(1):15-21. PubMed ID: 17204694
[TBL] [Abstract][Full Text] [Related]
15. Use of benzodiazepines before (18)F-FDG-PET/CT dual-phase imaging does not decrease the efficacy of the study.
Ozülker F; Ozülker T; Ozpaçacı T
Indian J Nucl Med; 2012 Jan; 27(1):24-9. PubMed ID: 23599594
[TBL] [Abstract][Full Text] [Related]
16. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients.
Barrio M; Czernin J; Yeh MW; Palma Diaz MF; Gupta P; Allen-Auerbach M; Schiepers C; Herrmann K
Nucl Med Commun; 2016 Dec; 37(12):1290-1296. PubMed ID: 27612034
[TBL] [Abstract][Full Text] [Related]
17. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization.
Choi JY; Lee KS; Kim HJ; Shim YM; Kwon OJ; Park K; Baek CH; Chung JH; Lee KH; Kim BT
J Nucl Med; 2006 Apr; 47(4):609-15. PubMed ID: 16595494
[TBL] [Abstract][Full Text] [Related]
18. Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.
Weber WA; Gatsonis CA; Mozley PD; Hanna LG; Shields AF; Aberle DR; Govindan R; Torigian DA; Karp JS; Yu JQ; Subramaniam RM; Halvorsen RA; Siegel BA; ;
J Nucl Med; 2015 Aug; 56(8):1137-43. PubMed ID: 25908829
[TBL] [Abstract][Full Text] [Related]
19. Can
Gupta M; Datta A; Choudhury PS; Dsouza M; Batra U; Mishra A
World J Nucl Med; 2017; 16(2):133-139. PubMed ID: 28553180
[TBL] [Abstract][Full Text] [Related]
20. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
